Email this article 
COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION WITH 13-VALENT CONJUGATE AND 23-VALENT POLYSACCHARIDE VACCINE IN PATIENTS WITH COPD
- Authors: PROTASOV AD1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 11, No 4 (2014)
- Pages: 12-17
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/583
- DOI: https://doi.org/10.36691/RJA583
- ID: 583
Cite item
Open Access
Access granted
Abstract
Comparative data on the clinical efficacy of vaccination in patients with chronic obstructive pulmonary disease (COPD) against pneumococcal infection using 13-valent conjugate vaccine (PCV-13) or 23-valent polysaccharide vaccine (PPV-23) is cited. Background. To evaluate a clinical efficacy (the number of exacerbations, courses of antimicrobial chemother- apy, hospitalizations) of PCV-13 and PPV-23 in patients with chronic obstructive pulmonary disease (COPD). Methods. The study involved 55 patients with COPD. Patients who met inclusion/exclusion criteria were divided in 2 groups: I group of patients received one dose of the vaccine «Prevenar-13» intramuscularly in the left shoul- der (n=32), II group received one dose of the vaccine «Pneumo-23» intramuscularly in the left shoulder (n=23). We estimated the number of exacerbations per year prior to vaccination and during the year after vaccination, the number of courses of antibiotic therapy for a year prior to vaccination and for a year after immunization, the number of hospitalizations for COPD exacerbation during the year prior to vaccination and during the year after immunization. Results. Vaccination of patients with COPD with PCV-13 or PPV-23 was characterized by the same high clinical efficacy, without the expressed benefits in favor of any drug. Conclusion. Vaccination of patients with COPD against pneumococcal infection with PCV-13 or PPV-23 is char- acterized by a high clinical efficacy. High cost of the 13-valent conjugate pneumococcal vaccine vs a polysac- charide vaccine additionally requires a proof of it’s benefit use in patients with COPD. Until such evidences and their wide representation in the scientific literature should be done vaccination of COPD patients with 13-valent conjugate vaccine is still discussable.
Full Text
References
- World Health Organization. Chronic obstructive pulmonary disease. 2012. Available at: http://www.who.int/mediacentre/ factsheets/fs315/en/index.html.
- Протасов А.Д. Иммунологический и клинический эф- фекты сочетанного применения вакцин против пнев- мококковой, гемофильной типа B инфекций и гриппа у больных с хронической обструктивной болезнью легких. Автореферат диссертации канд. мед. наук. М., 2012, 26 с.
- World Health Organization. 23-valent pneumococcal polysac- charide vaccine: WHO position paper. Wkly Epidemiol Rec. 2008, v. 83, p. 373-384.
- Чучалин А.Г. Современные подходы к вакцинопрофилак- тике пневмококковой инфекции у взрослых и пациентов групп риска: резолюция Междисциплинарного совета экспертов. Пульмонология. 2012, № 6, с. 139-142.
- Rodriguez-Roisin R., Anzueto A., Bourbeau J. et al. Global initiative for chronic obstructive lung disease. National Insti- tutes of Health, 2011, 80 p.
- Глобальная стратегия диагностики, лечения и профилак- тики хронической обструктивной болезни легких (пере- смотр 2011 г.). Под ред. А.С. Белевского. М., «Российское респираторное общество». 2012, 80 с.
Supplementary files
